News
Patient-Reported Outcomes Predict Mortality in Cutaneous Chronic GVHD
- Author:
- John Jesitus
Study findings are relevant to dermatologists in academic and transplant centers and the community who provide skin cancer screenings or other...
News
Adequate Transition of Epilepsy Care from Pediatric to Adult Is Often Lacking
- Author:
- John Jesitus
“We are not doing as good a job with planning for transition as we should.”
News
Retinal Perfusion Is Reduced During Migraine Attacks
- Author:
- John Jesitus
OCTA-derived measurements of retinal perfusion and related parameters are being studied as potential migraine biomarkers.
News
GVHD raises vitiligo risk in transplant recipients
- Author:
- John Jesitus
Graft-versus-host disease appears to raise vitiligo risk in transplant recipients, particularly those who receive hematopoietic stem cell...
News
Dupilumab-associated lymphoid reactions require caution
- Author:
- John Jesitus
In cases involving unexpected responses or atypical presentations, clinicians must have a low threshold for stopping dupilumab.
News
Guillain-Barré syndrome: Honing treatment strategies
- Author:
- John Jesitus
Classic subtypes of Guillain-Barré syndrome are varying manifestations of a shared disease process, novel insights into the disease indicate. This...
News
NPF provides guidance for virtual psoriasis visits
- Author:
- John Jesitus
A National Psoriasis Foundation position paper addresses ongoing management of psoriatic disease via telemedicine.
News
Pooled safety data analysis of tralokinumab reported
- Author:
- John Jesitus
Regarding safety areas of special interest, eye disorders classified as conjunctivitis, keratoconjunctivitis, or keratitis occurred more commonly...
News
NRS grants target rosacea’s underlying mechanisms
- Author:
- John Jesitus
The National Rosacea Society has funded studies to examine rosacea mechanisms via sequencing technology and by looking at lasers’ impact.
News
Serum dupilumab levels do not predict clinical response
- Author:
- John Jesitus
In a study of adults with eczema, dupilumab blood levels at 4 months bore no correlation with clinical responses or adverse events during the...